I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BLTI more than doubled this week I hope you got some. That will make my 3rd no brainer in a row.
JEDM .011 Unlike all my other picks here, this one is a HIGHLY SPECULATIVE play on bottom fishing with "hopes" of good news from the report that is due along with the good exposure from the CES show. Plus their subsitiy is to start trading on the German exchange.
Could be a momo and that seems to be what everyone else here is looking for. Could lose it all too. I cannot add to my no-brainer picks but I thought I would throw this one out there anyway.
I have not done a lot of DD on this one so if someone does not like this stock please shoot it down with some facts and you will be doing everyone a favor.
Quote: "Please show me one example of how he has transferred money to his own pockets. Just one..."
Check the history and decide for yourself. When it comes to JB local info this person has been very accurate...
"John was offering a family & friend deal goin for 2 buck's a share and some opted to buy in again"...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=55879023
Can you find any $2 pipe in the filings? Can you find one thing about JB that you know for sure that this person was wrong about? Read their other posts and then tell me they do not know JB.
BLTI went KABOOM :) two down (or up) and three to go. As a general rule, I usually take profits on any huge spike and then let the stock settle down for a few days before buying back. I still like all of these stocks long-term and the I accept the risk of selling too soon or sometimes a pullback never happens.
Glad to see that you are OK. Just remember that it is only money and you can't take it with you. Maybe you should get a lawyer that has knowledge of these types of cases (ITRO vs NIR) and see what they think the probable outcome will be? I see this lawsuit as the next real catalyst for stock movement (win or lose) IMHO. If insiders ever decide to buy common ITRO stock (open market), that would tell us they believe that the worst is over.
PSTI went KABOOM :) APNT MTRE NNVC BLTI are all up and on the launch pad. Maybe not this week or this month but they are all looking good long-term as in NO BRAINER!!! When these types of companies go into orbit they rarely drop back to earth.
BLTI $1.48 I don't know how many picks I can get here but I would also like to add BLTI (dental laser). I'm thinking the deal last year with P&G should start hitting the books this year.
My other picks:
APNT - Nano Company with patents licensed for products (2010 is first year profitable)
MTRE - see recent LOI 4 businesses converging
NNVC - Novel Virus treatment that makes a "functional cure" for HIV
PSTI - Stem cells - Hard run but hardly done :)
GLTY
Did anyone else get any PSTI on Monday? I got some earlier that I plan to hold but I was hoping to add more on a pullback but I'm not complaining. Guess I should have put it onto the board as a call after all - lol
This blog also may have created some interest. The timing fits.
http://www.altenergystocks.com/archives/2011/01/energy_storage_the_valley_of_death_and_the_elephant_hunters_1.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+AlternativeEnergyStocks+%28AltEnergyStocks.com%29
Anyone here actually use their software/headset? Are there any convertible debts or dilution issues?
52 week highs are just too common to report on PSTI. :)
52 week highs are just too common to report on MBLTY - lol
Looks like the bottom has been put in IMHO. I got some shares today.
Artificial Life Announces 96% Increase in iPhone/iPod/iPad Downloads
Artificial Life (OTCBB:ALIF)
Intraday Stock Chart
Today : Thursday 13 January 2011
Click Here for more Artificial Life Charts.
Artificial Life, Inc., (OTC Bulletin Board: ALIF) (http://www.artificial-life.com), today revealed its current iPhone/iPod and iPad title sales, download numbers and key ranking statistics.
The total number of iPhone/iPod/iPad application downloads generated for the year of 2010 was over 15.7 million in comparison to 8 million downloads in 2009.
As of December 31st, 2010, the Company has produced and released 36 applications for the iPhone, iPod touch and iPad. The top title was downloaded for over 6.2 million times, the second most for over 3.4 million times, and the third most for close to 3.1 million times. The average number of downloads per game was about 0.66 million. Paid iPhone games were sold at between USD 0.99 to USD 4.99 with an average price per game of USD 2.27. All the new games released have achieved Top 100 or higher download rankings in their categories. Artificial Life's (ALIF) games have reached #1 on Apple App Store Top Charts in over 74 countries or 83% of all the offered countries.
The Company has also gained successful results from penetrating the iPad market. For instance, since the launch of Linkin Park 8-Bit Rebellion! iPad Edition in April, 2010, the game has firmly remained in US Top 20 Paid Music Apps in many countries around the world. Other iPad games have also continued to secure their places in the Top 50 charts even months after their releases. GluCoMo™, the first newly launched healthcare iPhone application for monitoring and coaching diabetic patients, has also received positive results with the achievement of being in the US Top 50 Healthcare & Fitness Apps. The highly popular iPhone games: Amateur Surgeon, Red Bull Racing Challenge, and iSink U have also been ported onto the iPad platform with enhanced features and gameplay.
Among the 36 produced games, 26 are based on licensed and branded intellectual property from a variety of licensors while 10 games are based on Artificial Life's proprietary IP. The games have been sold in a total of 89 countries worldwide. The distribution of game downloads by region is: 44% in North America, 34% in Europe and Africa, 17% in Asia Pacific, 3% in Latin America and 2% in the Middle East. The Top 5 countries in terms of download numbers for our products are: United States, United Kingdom, France, Germany, and Canada (with 40%, 10%, 5%, 5% and 5% of downloads respectively).
"2010 has been a very successful year for Artificial Life. Our R&D and technology advancement have greatly contributed in delivering outstanding iPhone/iPod/iPad applications. We will continue to invest in R&D and new game and business apps design to provide highest quality games and business applications for the iPhone and iPad in the year 2011," said Eberhard Schoneburg, CEO of Artificial Life, Inc.
iPod and iPhone are trademarks of Apple Inc., registered in the US and other countries. iPad a trademark of Apple Inc. App Store is a service mark of Apple Inc.
About Artificial Life, Inc.
Artificial Life, Inc. has been a pioneer in artificial intelligence and mobile technology since its inception in Boston in 1994. We are a public US corporation (OTC BB: ALIF) with listing on the Frankfurt Stock Exchange (Frankfurt: AIF.F; Xetra: AIF.DE) and headquarters in Hong Kong. Our production center is in Hong Kong and we have additional offices in Berlin, Germany (EMEA headquarters) and Tokyo, Japan. As a leading provider of broadband mobile content and technology solutions in the world, we develop and sell a wide range of mobile applications for 3G, 3.5G and 4G network-enabled mobile (smart) phones. Currently our main business areas are: high quality 3D interactive (massive multiplayer) mobile games, mobile participation television, mobile business applications and our mobile commerce technology platform OPUS-M. We are supporting all major mobile phone operating systems and platforms. Recognized internationally for outstanding content quality and technology we have received many international awards and have been ranked one of the fastest growing companies in Asia Pacific by Deloitte.
For more information about Artificial Life, Inc., please visit our website www.artificial-life.com or our product websites: www.botme.com, www.mopa-tv.com, www.opus-m.com, www.glucomo.com, www.greencortex.com .
Facebook: http://www.botme.com/ref/alife-fb
Twitter: http://twitter.com/alifegames
MySpace: http://www.myspace.com/artificial_life_inc
Youtube: http://www.youtube.com/user/alifegames
Forward-Looking Statements:
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our future results of operations, financial condition and business prospects. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of these terms or other comparable terminology. Although such statements are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on them. These statements involve risks and uncertainties, and actual market trends or our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied in these forward looking statements for a variety of reasons. Potential risks and uncertainties include, but are not limited to, our ability to obtain additional funding to operate and grow our business; the unproven potential of our mobile gaming business model; changing consumer preferences and uncertainty of market acceptance of our products; timely adoption and availability of 3G mobile technology; market acceptance for use of mobile handheld devices to play the interactive games; unpredictable mobile game development schedules; our reliance on a relatively small number of brands; our ability to license brands from others; our dependence upon resellers and telecommunication carriers and operators to distribute our products; our ability to successfully develop, introduce, and sell new or enhanced products in a timely manner; and the timing of new product announcements or introductions by us or by our competitors. For additional discussion of these risks and uncertainties and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB filed on March 16, 2010. We assume no obligation to update any forward-looking statements, which apply only as of the date of this press release.
For more information on ARTIFICIAL LIFE, INC., please contact:
Artificial Life IR and PR Contact:
Adeline Law
Tel: (+852) 3102 2800
ir@artificial-life.com
SOURCE Artificial Life, Inc.
NNVC $1.50
I may not have made as high of a percentage with APNT and MTRE as some the "superstars" but I am happy that the only two picks I made are still higher by a decent percentage AND I think they will be much, much, higher a year from now IMHO.
I was thinking of calling PSTI the other day but it just gap today and I would hate to recommend it then see it pull back but I really like it long-term. I do think I can safely call NNVC nobrainer as I think it is finally ripe for a long-term run JMHO
You seem to be reasonable and desire the truth so maybe you can refute this claim that JB was able to personally gain $4.8 million through the transfer of assets from Expedite 2 to TRTN (which is now JBII) ...
http://siliconinvestor.advfn.com/readmsg.aspx?msgid=27039491
(for additional details you will need to follow the thread backwards)
If this information is not accurate, I would really like to know.
Thanks
Cephalon, Inc. Announces Positive Interim Results From Mesoblast Limited's Phase 2 Trial Of Revascor
2:41am EST
Cephalon, Inc. announced positive interim results from Mesoblast Limited's ongoing multi-center Phase 2 trial of its off-the-shelf adult stem cell product Revascor for patients with congestive heart failure. Patients who received a single injection of Revascor into damaged heart muscle have had less cardiac events, deaths, and hospitalizations during the follow-up period to date than control patients. Cephalon and Mesoblast have entered into a strategic alliance to develop and commercialize Mesoblast's Mesenchymal Precursor Cell (MPC) therapeutics for hematopoietic stem cell transplantation in cancer patients, as well as degenerative conditions of the central nervous and cardiovascular systems, including congestive heart failure. Mesoblast is evaluating the safety and efficacy of Revascor in a randomized, placebo-controlled Phase 2 trial in 60 patients with moderate-severe congestive heart failure. A single injection of Revascor at one of three progressively increasing doses has been administered to 45 patients randomized to receive cell therapy in addition to standard-of-care, while 15 control patients have been concomitantly randomized to receive standard-of-care alone. The trial will be completed when all available patients have been followed-up for 12 months. A scheduled interim analysis of safety and of time-dependent hard efficacy endpoints was performed when the last of the 60 enrolled patients had completed six months of follow-up in December 2010.
Pluristem’s Potential Value Highlighted by Cephalon-Mesoblast Deal
Written by Ray Dirks
Wednesday, 05 January 2011 02:06
Mesoblast Ltd. (ASX: MSB: AX) and Cephalon (NASDAQ: CEPH) announced a deal that I believe gives insights into the potential value of Pluristem Therapeutics, Inc. (NASDAQ: PSTI).
PSTI and MSB are both cell therapy companies and are considered comparables. PSTI, an American company with headquarters in Haifa Israel, uses the Human placenta (afterbirth) as a source of their therapeutic cells while MSB, an Australian company, uses bone marrow as their source of cells. Additionally, PSTI grows their cells in-house in a proprietary bioreactor while it is felt that MSB outsources the expansion of their cells where they are grown in Petri dishes or tissue flasks.
Both PSTI and MSE have conducted several pre-clinical studies indicating their respective cells are potentially effective in a variety of indications including orthopedic, cardiovascular, hematological and neurological diseases. PSTI has recently completed two Phase I/IIa trials in Europe and Germany in peripheral vascular disease while MSB is entering Phase III trials as an alternative to bone marrow transplant in hematological malignancies and in Phase II trials for orthopedic and cardiovascular indications. Therefore, it is safe to assume that MSB is “ahead” of PSTI in terms of number of clinical indication for which their cells are in trials However, I believe PSTI will continue to show progress and “get to where MSB is” over the next year.
The highlights of the CEPH-MSB deal are as follows:
1. CEPH has licensed MSB’s cells for the following indications:
a. Cardiovascular disease – including congestive heart failure and acute myocardial infarction.
b. Neurodegenerative disease – including Parkinson’s disease, Huntington’s chore and Alzheimer’s disease.
c. In oncology – for the expansion of hematopoietic precursor cells in hematological malignancies.
2. CEPH Will Pay 50% of all preclinical cost (through Phase IIa) for the chronic neurodegenerative disease indications and 100% of the costs for clinical development post IIa for all indications licensed.
3. CEPG to Pay $100 Million to MSB upfront on signing the deal and an additional 30 Million after share holder approval to sell 19.9% of MSB’s equity to CEPH at $4.35 ( a 45% premium to MSB’s 30 day average at the time of the deal).
4. CEPH will pay milestone payments to MSB that could amount to as much as $1.7 Billion.
5. CEPH receives sales and marketing rights for the above indications.
MSB’s market value is currently approximately $745 Million while PSTI’s market value is approximately $35 Million. As PSTI enters clinical trials for the other indication with their proprietary placental-expanded (PLX) cells, their market value should reasonably approach or potentially exceed the market value of MSB because, in my opinion, PSTI’s cells are easier to obtain and grow and are potentially better cells therapeutically.
Ergo, my opinion is to accumulate PSTI’s Stock.
Related articles
* Cephalon in Stem Cell Deal - Analyst Blog (zacks.com)
* Pluristem Therapeutics Approved for Dual Listing on the Tel Aviv Stock... (news.google.com)
Disclosure: No Positions
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section
Read the full report: http://biomedreports.com/2011010562000/pluristems-potential-value-highlighted-by-cephalon-mesoblast-deal.html#ixzz1AgAnK0K8
http://biomedreports.com/2011010562000/pluristems-potential-value-highlighted-by-cephalon-mesoblast-deal.html
I like it even more today :) Another 52 week high!!!
You will need to be able to read Australian - lol
http://www.reuters.com/finance/stocks/financialHighlights?symbol=MSB.AX
Wow... Looks like this might actually happen after all these years:) $.14 cents is starting to look like a bargain. Might save some dry powder for the RS just in case the price drops?
This could be a good year for TINY if a few of their companies do an IPO. Closed at $4.36 today and I'm calling it a long-term buy...
"IPOs Expected to Have Strong Year As Stocks Recover"
On Friday January 7, 2011, 3:13 pm EST
U.S. companies are expected to go public this year at the best pace in three years, as investors regain confidence in stocks and seek more risk.
Among the first to test the waters will be TV ratings company Nielsen Holdings, while a big wild card for the market will be whether one of the young, fast-growing internet companies like LinkedIn or Groupon decide to go with an initial public offering (IPO).
A rebound from the two-year slump in the U.S. IPO market started last year and should accelerate, industry experts say. There are currently more than 130 companies in the pipeline, mostly U.S.-based, and at least twice as many are believed to be waiting in the wings.
"U.S. IPOs will step up in activity due to recent clarity on tax rates, the Federal Reserve's QE2 effort to push investors into the equity market and the prospects of a more business-friendly federal government," says IPO research and management firm Renaissance Capital in a recent report.
The firm's research director Paul Bard told CNBC that the IPO market will continue to take its cue from broader equity markets, but he sees the environment as very positive.
"Companies are feeling better about their business and growth prospects; money is coming to equity funds, and investors are making money in IPOs not only on the first day, but after the first day as well," he said.
Bard sees the growing activity on private exchanges as an indication of a strong desire among institutional investors for young, U.S. growth companies.
"This means should they decide to move forward with IPOs, there should be strong demand from the buy side," he said.
The biggest surprise of the year may come from the swollen shadow IPO pipeline that includes some high-profile names.
Peter Falvey, a managing director at Morgan Keegan, says the real wild card in 2011 will be hyper-growth Internet companies currently on sidelines like Facebook, LinkedIn, Groupon, Zynga or Twitter.
"If one of them files, this will bring attention to the IPO market unlike anything we have seen since at least Google went public in 2004," Falvey said.
Just this week, reports surfaced that Goldman Sachs (NYSE: gs) has offered its wealthy private clients an opportunity to invest in Facebook. The reported investment raised Facebook's valuation to a jaw-dropping $50 billion.
According to Falvey, this gives Facebook the luxury of putting off an IPO for some time. In fact, the latest reports say the company will go public or disclose financial information no earlier than April 2012.
"Their early investors aren't clamoring for liquidity, and they won't want to disclose their numbers to the public through filings until necessary," Falvey said. Staying private also makes it easier for Facebook to further experiment with its revenue model, he adds.
This year, the U.S. IPO market will see more traditional growth issuers, with U.S. small cap tech and consumer companies picking up activity, expects Bard of Renaissance Capital. The healthcare sector is also anticipated to stage a comeback, after being notably absent last year due to uncertainties surrounding policy reform.
Private-equity IPOs, which struggled in 2010, should increase in both number and volume, according to Bard.
"We expect several large $1billion-plus private equity IPOs," he said. However, investors will continue to push for lower prices.
One of the first blockbuster offerings of the year may be Nielsen Holdings. The company could raise $2 billion, becoming the largest PE-backed public offering in a decade. Bard says keep an eye on HCA, the largest private hospital operator in the country. This IPO could set a record, raising close to $5 billion. Other notable IPOs currently in the pipeline: Toys "R" Us, Kinder Morgan, and Skype.
http://finance.yahoo.com/news/IPOs-Expected-to-Have-Strong-cnbc-1144749264.html;_ylt=Avz7jnHQfRVoh9j7UUhBStS7YWsA;_ylu=X3oDMTE1Ym40cTd0BHBvcwM0BHNlYwN0b3BTdG9yaWVzBHNsawNpcG9zZXhwZWN0ZWQ-?x=0&sec=topStories&pos=1&asset=&ccode
I like PSTI and own some shares but your reference to "Pink" is not fair as Mesoblast is traded on the AX and the MBLTY is a 5:1 ADR just to be accurate. This is common for foreign stocks to offer access to US markets while fully reporting on their home exchange (see Nintendo NTDOY.PK as another example).
Touched a nice 52 week high again today :)
Nice strong day:)
I like the potential for NNVC but if you want to see my others you will need to follow the "my stocks" link in my profile (at least until my newsletter gets out - lol).
Hey, I called his best winner before he did...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44692650
And it was not even my best pick - I need to start a newsletter. LOL
The one looser pick I did make I also quickly changed my recommendation in that same thread when the situation changed.
I also have some NNVC and poke my head in here now and then.
Happy New Year
? APNT MTRE :)
Did not stay under a dollar for long. Looking much better for good growth.
If Mary and Joseph were on Facebook...
If Mary and Joseph were on Facebook...
Enjoy the three day weekend and don't think about stocks. You can make or lose money on JBII next week. However, if your going to be at your computer anyway then watch this youtube video...
Merry Christmas one and all.
and a Happy New Year too!
I hope JBII goes well for everyone even though my personal comfort level here has been exceeded.
Market cap is very low for a profitable & reporting company with good cash flow such a great IP portfolio making progress on so many high potential areas, IMHO.
It may drop some with the low float and waiting on news (I hope so cause I would like to buy more). I just hope the momo crowd does not discover just how fast this moves on volume an ruin our buying op.
MARK THIS:
APNT is looking good to me at $.38 Check this post in a year and see if I'm right.
:)
Hey, nice day here :) The next step is supposed to be an independent audit of the efficiency which was going to take 30 days. I would guess that CRA would do this. I would think that a 7 day audit would be sufficient to get a fair analysis of the profitability. Maybe we could get a 7 day report of one full week and then do the media event while they continue to do a full month audit? Should not be hard to calculate the monthly expenses and get a close estimate of how they would break down on a weekly basis for an accurate audit.
How about if we try NOT to get ahead of JB and let him set the expectations for the future?
Finally, some good news with teeth:)
Do you really want the truth?
The last SEC filed document (2007) showed an Accumulated deficit of (32,129,821). Without updates from the company, you are left to speculate if it is currently higher or lower.
The increase revenue numbers mean nothing without also knowing the cost of production and the cost of servicing the debt.
The lawsuit is about Dr. Whitney giving insider information to NIR about how bad the finances were at ITRO. Do you trust that he will come clean now and tell everyone just how bad/good the actual finances are?
This may be a good stock someday but years of damage on investors confidence will take a long time to repair an it starts with an honest accounting of where ITRO stands financially and the three plus years of SEC reports will take a lot of time and money just to get started down the right path. IMHO
Mesoblast Limited (ASX:MSB) Clear To Proceed With Angioblast Acquisition
Melbourne, Nov 19, 2010 (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the required period for any antitrust objection under the United States Hart-Scott-Rodino(HSR) anti-trust improvement Act 1976 in respect of its acquisition of Angioblast Systems Inc. has expired.
On completion of the acquisition, the enlarged Mesoblast Group will have on issue approximately 250 million shares and at today's share price, a market capitalization approaching A$750 million.
Under the HSR Act, given the size of the transaction, both entities involved in the merger, acquisition, or consolidation were required to file notifications to the United States anti-trust authorities and to observe the statutory waiting period before consummating the transaction.
The parties are now able to proceed with finalization of all merger conditions.
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
Tel: +61-3-9639-6036
Mob: +61-419-228-128
Email: julie.meldrum@mesoblast.com
http://www.mesoblast.com
Link: http://www.abnnewswire.net/media/en/docs/64229-ASX-MSB-345915.pdf